Logo

Janssen's Stelara (ustekinumab) Receives the US FDA's Approval for the Treatment of Active Psoriatic Arthritis in Pediatric Patients

Share this
Janssen's Stelara (ustekinumab) Receives the US FDA's Approval for the Treatment of Active Psoriatic Arthritis in Pediatric Patients

Janssen's Stelara (ustekinumab) Receives the US FDA's Approval for the Treatment of Active Psoriatic Arthritis in Pediatric Patients

Shots:

  • The approval was based on the PK data from the P-III (PSTELLAR/CADMUS/CADMUS Jr) trial in adult & pediatric patients with plaque PsO & (PSUMMIT I & II) trial in adult patients with active PsA for Stelara
  • The results showed that ustekinumab's PK exposure in pediatric PsO patients with active PsA was consistent with P-III trials in pediatric PsO patients without active PsA along with adult patients with PsO or with active PsA. The pediatric PsO patients with active PsA had similar data on similar effectiveness EPs
  • The company launched STELARA withMe support program that offers access to patients to use Stelara & provides information on insurance coverage, out-of-pocket costs, treatment support & identifies options for affordable treatment to patients

Ref: johson and johnson | Image: johson and johnson

Click here to­ read the full press release 

Neha

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions